enow.com Web Search

Search results

1. Results from the WOW.Com Content Network

2. What to Know About Complementary Therapies for Prostate Cancer

   www.aol.com/lifestyle/know-complementary...

   “Fatigue is a huge issue for prostate cancer patients, especially post-treatment,” Balneaves says. “Exercise, as much as a person’s able to, does seem to alleviate fatigue.”

3. White button mushroom extract may help slow progression of ...

   www.aol.com/white-button-mushroom-extract-may...

   After treatment with white button mushroom extract in mice and patients with prostate cancer, scientists discovered a decline in the amount of immune-suppressing cells in tumors.

4. Candel Therapeutics Stock Surges Over 100% - Here's Why - AOL

   www.aol.com/candel-therapeutics-stock-surges...

   A significant increase in the proportion of patients achieving a prostate-specific antigen (PSA) nadir (<0.2 ng/ml) was observed in the treatment arm compared to the placebo control arm (67.1% vs ...

5. Prostvac - Wikipedia

   en.wikipedia.org/wiki/Prostvac

   PROSTVAC is being developed in partnership with the National Cancer Institute under a formal Cooperative Research and Development Agreement and has been the subject of multiple ongoing and completed clinical studies, including the global Phase 3 PROSPECT study underway in patients with asymptomatic or minimally symptomatic metastatic prostate cancer (mCRPC). [2]

6. Management of prostate cancer - Wikipedia

   en.wikipedia.org/wiki/Management_of_prostate_cancer

   Surgical removal of the prostate, or prostatectomy, is a common treatment either for early-stage prostate cancer or for cancer that has failed to respond to radiation therapy. The most common type is radical retropubic prostatectomy , when the surgeon removes the prostate through an abdominal incision.

7. STAMPEDE (clinical trial) - Wikipedia

   en.wikipedia.org/wiki/STAMPEDE_(clinical_trial)

   Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy (STAMPEDE) is a clinical trial investigating treatments for high risk or terminal prostate cancer. Recruitment started in 2005 and ended in 2022; as of January 2020, over 10,000 participants had joined the trial.